Advertisement

Topics

Matrisys Bioscience Announces First Patient Dosed In Phase IIA Clinical Trial With Live Staphylococcus Hominis Bacteria For The Treatment Of Atopic Dermatitis

20:00 EDT 20 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Matrisys Bioscience Announces First Patient Dosed In Phase IIA Clinical Trial With Live Staphylococcus Hominis Bacteria For The Treatment Of Atopic Dermatitis

NEXT ARTICLE

More From BioPortfolio on "Matrisys Bioscience Announces First Patient Dosed In Phase IIA Clinical Trial With Live Staphylococcus Hominis Bacteria For The Treatment Of Atopic Dermatitis"

Advertisement
Quick Search
Advertisement
Advertisement